These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 983808)

  • 1. Acetylator phenotype in patients with hydralazine-induced lupoid syndrome.
    Strandberg I; Boman G; Hassler L; Sjöqvist F
    Acta Med Scand; 1976; 200(5):367-71. PubMed ID: 983808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility.
    Batchelor JR; Welsh KI; Tinoco RM; Dollery CT; Hughes GR; Bernstein R; Ryan P; Naish PF; Aber GM; Bing RF; Russell GI
    Lancet; 1980 May; 1(8178):1107-9. PubMed ID: 6103441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical consequences of polymorphic acetylation of basic drugs.
    Drayer DE; Reidenberg MM
    Clin Pharmacol Ther; 1977 Sep; 22(3):251-8. PubMed ID: 19187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydrallazine-induced lupus erythematosus-like syndrome in a patient of the rapid acetylator phenotype.
    Harland SJ; Facchini V; Timbrell JA
    Br Med J; 1980 Jul; 281(6235):273-4. PubMed ID: 7427242
    [No Abstract]   [Full Text] [Related]  

  • 7. Hydralazine sensitivity: clinical features, autoantibody changes and HLA-DR phenotype.
    Russell GI; Bing RF; Jones JA; Thurston H; Swales JD
    Q J Med; 1987 Oct; 65(246):845-52. PubMed ID: 3329739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cadralazine challenge in patients with previous hydralazine-induced lupus: a 6-month study.
    Pålsson L; Weiner L; Englund G; Henning M
    Clin Pharmacol Ther; 1989 Aug; 46(2):177-81. PubMed ID: 2758727
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acetylator phenotype and lupus erythematosus.
    Uetrecht JP; Woosley RL
    Clin Pharmacokinet; 1981; 6(2):118-34. PubMed ID: 7011656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spontaneous systemic lupus erythematosus and acelylator phenotype.
    Larsson R; Karlsson E; Molin L
    Acta Med Scand; 1977; 201(3):223-6. PubMed ID: 848361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective study of immunologic effects of hydralazine in hypertensive patients.
    Litwin A; Adams LE; Zimmer H; Foad B; Loggie JH; Hess EV
    Clin Pharmacol Ther; 1981 Apr; 29(4):447-56. PubMed ID: 6970646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isoniazid disposition, comparison of isoniazid phenotyping methods in and acetylator distribution of Japanese patients with idiopathic systemic lupus erythematosus and control subjects.
    Horai Y; Ishizaki T; Sasaki T; Koya G; Matsuyama K; Iguchi S
    Br J Clin Pharmacol; 1982 Mar; 13(3):361-74. PubMed ID: 7059436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydralazine, antinuclear antibodies, and the lupus syndrome.
    Mansilla-Tinoco R; Harland SJ; Ryan PJ; Bernstein RM; Dollery CT; Hughes GR; Bulpitt CJ; Morgan A; Jones JM
    Br Med J (Clin Res Ed); 1982 Mar; 284(6320):936-9. PubMed ID: 6802356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and lupus nephritis.
    Ihle BU; Whitworth JA; Dowling JP; Kincaid-Smith P
    Clin Nephrol; 1984 Nov; 22(5):230-8. PubMed ID: 6240359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug acetylation phenotype unrelated to development of spontaneous systemic lupus erythematosus.
    Morris RJ; Freed CR; Kohler PF
    Arthritis Rheum; 1979 Jul; 22(7):777-80. PubMed ID: 454504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Procainamide-induced lupus erythematosus-like syndrome in relation to acetylator phenotype and plasma levels of procainamide.
    Sonnhag C; Karlsson E; Hed J
    Acta Med Scand; 1979; 206(4):245-51. PubMed ID: 92167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug acetylation and expression of lupus erythematosus.
    Marsden JR; Mason GG; Coburn PR; Rawlins MD; Shuster S
    Eur J Clin Pharmacol; 1985; 28(4):387-90. PubMed ID: 4029245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunologic effects of hydralazine in hypertensive patients.
    Litwin A; Adams LE; Zimmer H; Hess EV
    Arthritis Rheum; 1981 Aug; 24(8):1074-8. PubMed ID: 6974554
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.